A Phase II , Single-Center, Open Label study of Oral Panobinostat (LBH589) when administered in combination with Lenalidomide and weekly Dexamethasone in patients with multiple myeloma
ID Number 12-0469Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The study drug, panobinostat (LBH589), is made by Novartis Pharmaceuticals Corporation. Panobinostat has not yet been approved by the Food and Drug Administration (FDA) and thus is considered an experimental drug in this research study. Panobinostat is not available to people “on the market” (available for you to buy). It is only available in clinical trials. Panobinostat is a drug that may slow down the growth of multiple myeloma or kill multiple myeloma cells by blocking certain enzymes (proteins produced by cells). Panobinostat has shown effects against cancers such as multiple myeloma in laboratory studies and in studies using animals; however, it is not known if this medicine will show the same activity in humans. As of 31st December 2009, a total of 1116 people have already received treatment with panobinostat.
The purpose of this clinical research study is to find out the effects of panobinostat when given to people with multiple myeloma in combination with the drugs lenalidomide and dexamethasone. The safety of this combination of drugs will also be studied. A person’s physical state, changes in the state of their multiple myeloma, and laboratory findings taken while on-study will help the researchers decide if panobinostat combined with dexamethasone and lenalidomide is safe and effective.
To be able to participate in this research study a person must have been diagnosed with multiple myeloma.
Recruiting Patients: No